Vabysmo Demonstrates Sustained Two-Year Results in a Difficult-to-Treat Form of Neovascular Age-Related Macular Degeneration – Roche
Roche announced new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo (faricimab), presented at the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress in Australia. The results showed… read more.

